News articles about Transcat (NASDAQ:TRNS) have been trending somewhat negative recently, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Transcat earned a media sentiment score of -0.04 on Accern’s scale. Accern also assigned news coverage about the scientific and technical instruments company an impact score of 46.6062976704274 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Separately, Dougherty & Co started coverage on shares of Transcat in a research report on Wednesday, August 23rd. They issued a “buy” rating and a $20.00 price target for the company.

Shares of Transcat (NASDAQ:TRNS) traded down 1.66% during trading on Friday, reaching $14.80. 25,166 shares of the company’s stock traded hands. The company has a market capitalization of $105.51 million, a price-to-earnings ratio of 23.49 and a beta of 0.42. The stock has a 50-day moving average of $13.40 and a 200-day moving average of $12.59. Transcat has a 1-year low of $10.00 and a 1-year high of $15.15.

Transcat (NASDAQ:TRNS) last released its quarterly earnings data on Tuesday, July 25th. The scientific and technical instruments company reported $0.12 earnings per share (EPS) for the quarter. Transcat had a net margin of 3.03% and a return on equity of 10.37%. The company had revenue of $36.28 million during the quarter. On average, equities analysts predict that Transcat will post $0.64 EPS for the current fiscal year.

In other Transcat news, Director Paul D. Moore sold 4,000 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $13.00, for a total transaction of $52,000.00. Following the completion of the sale, the director now directly owns 57,698 shares in the company, valued at $750,074. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Carl E. Sassano sold 7,500 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $13.02, for a total transaction of $97,650.00. Following the sale, the director now owns 79,075 shares of the company’s stock, valued at $1,029,556.50. The disclosure for this sale can be found here. 8.80% of the stock is owned by insiders.

TRADEMARK VIOLATION NOTICE: This article was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/10/07/somewhat-critical-news-coverage-somewhat-unlikely-to-impact-transcat-trns-stock-price.html.

Transcat Company Profile

Transcat, Inc is a provider of calibration and laboratory instrument services and a distributor of professional grade test, measurement and control instrumentation. The Company conducts its business through two segments: service (Service) and distribution (Distribution). Through the Service segment, the Company offers calibration, repair, inspection, analytical qualifications, preventative maintenance and other related services, a majority of which are processed through its asset management system, CalTrak (CalTrak).

Insider Buying and Selling by Quarter for Transcat (NASDAQ:TRNS)

Receive News & Ratings for Transcat Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transcat Inc. and related companies with MarketBeat.com's FREE daily email newsletter.